Pirfenidone is InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis to reduce decline in lung function.
The FDA has announced that it has approved a new drug to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.
Hilgartner, now 67, was diagnosed with idiopathic pulmonary fibrosis (IPF), one of the more lethal forms of severe fibrotic conditions that afflict more than 10 million Americans.